Wall Street analysts expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to report sales of $4.33 million for the current quarter, Zacks reports. Three analysts have made estimates for Collegium Pharmaceutical’s earnings. The lowest sales estimate is $3.62 million and the highest is $4.84 million. The firm is expected to issue its next quarterly earnings results on Wednesday, August 9th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full-year sales of $4.33 million for the current fiscal year, with estimates ranging from $18.70 million to $30.08 million. For the next year, analysts expect that the business will report sales of $72.59 million per share, with estimates ranging from $65.55 million to $87.67 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.19. The business had revenue of $2.17 million for the quarter, compared to the consensus estimate of $3.55 million.

COLL has been the subject of several analyst reports. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, March 14th. Jefferies Group LLC set a $24.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Saturday, March 25th. Janney Montgomery Scott reissued a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, June 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, June 9th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $22.83.

In other news, insider Paul Brannelly acquired 10,000 shares of the firm’s stock in a transaction on Friday, May 12th. The stock was acquired at an average price of $9.18 per share, with a total value of $91,800.00. Following the completion of the purchase, the insider now directly owns 110,227 shares in the company, valued at $1,011,883.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 25.76% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the company. State Street Corp increased its stake in shares of Collegium Pharmaceutical by 46.1% in the fourth quarter. State Street Corp now owns 289,219 shares of the specialty pharmaceutical company’s stock valued at $4,530,000 after buying an additional 91,287 shares during the last quarter. FMR LLC increased its stake in shares of Collegium Pharmaceutical by 20.2% in the fourth quarter. FMR LLC now owns 915,673 shares of the specialty pharmaceutical company’s stock valued at $14,257,000 after buying an additional 153,600 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Collegium Pharmaceutical by 98.2% in the fourth quarter. Franklin Resources Inc. now owns 1,797,902 shares of the specialty pharmaceutical company’s stock valued at $27,994,000 after buying an additional 890,868 shares during the last quarter. Eventide Asset Management LLC increased its stake in shares of Collegium Pharmaceutical by 3.4% in the fourth quarter. Eventide Asset Management LLC now owns 2,077,751 shares of the specialty pharmaceutical company’s stock valued at $32,351,000 after buying an additional 67,473 shares during the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at about $3,063,000. 82.30% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was posted by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/06/20/4-33-million-in-sales-expected-for-collegium-pharmaceutical-inc-coll-this-quarter.html.

Collegium Pharmaceutical (NASDAQ:COLL) traded up 4.23% on Friday, reaching $11.59. The company’s stock had a trading volume of 299,246 shares. The company’s market capitalization is $341.42 million. The firm has a 50-day moving average of $9.28 and a 200-day moving average of $12.94. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.55.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.